A gene therapy for heart failure being developed by Bayer’s AskBio unit has been granted fast-track status by the FDA, shortly after it showed preliminary signs of efficacy in a phase 1 trial.
The FDA granted a fast track designation to ALE-P02 for patients with CLDN1-positive squamous solid tumors. The FDA granted fast track designation to ALE.P02, a anti–Claudin-1 (CLDN1) antibody-drug ...
The FDA has awarded the fast-track designation for the CKD indication based on that result, as well as the promise of an ongoing trial – EMPA-KIDNEY – which is looking at kidney disease ...
Applications for cohort 10 of the Fast Track programme are now closed. The application window for cohort 11 opens in April 2025 and is open to both detectives and uniform officers. The aim of the ...